Invention Grant
- Patent Title: AGR2 blocking antibody and use thereof
- Patent Title (中): AGR2阻断抗体及其用途
-
Application No.: US14130767Application Date: 2012-07-05
-
Publication No.: US09574012B2Publication Date: 2017-02-21
- Inventor: Dawei Li , Zhenghua Wu , Hao Guo , Qi Zhu , Dhahiri S. Mashausi
- Applicant: Dawei Li , Zhenghua Wu , Hao Guo , Qi Zhu , Dhahiri S. Mashausi
- Applicant Address: CN Shanghai CN Shanghai
- Assignee: Sanofi (China) Investment Co., Ltd. Shanghai Branch,Shanghai Jiao Tong University
- Current Assignee: Sanofi (China) Investment Co., Ltd. Shanghai Branch,Shanghai Jiao Tong University
- Current Assignee Address: CN Shanghai CN Shanghai
- Agency: Lathrop & Gage LLP
- Agent James H. Velema, Esq.
- Priority: CN201110186469 20110705
- International Application: PCT/CN2012/000926 WO 20120705
- International Announcement: WO2013/004076 WO 20130110
- Main IPC: C07K16/40
- IPC: C07K16/40 ; A61K39/395 ; C12P21/08 ; A61K45/06 ; C07K16/22 ; A61K39/00
Abstract:
Disclosed is an AGR2 blocking monoclonal antibody, and in particular, a humanized monoclonal antibody for blocking AGR2. Also disclosed is a pharmaceutical composition containing the antibody and a method for preparing the same, and a use of the antibody in blocking tumor growth and metastasis.
Public/Granted literature
- US20140328829A1 AGR2 BLOCKING ANTIBODY AND USE THEREOF Public/Granted day:2014-11-06
Information query
